Our Commitment to
Global Public Health

For 130 years, Johnson & Johnson has been committed to improving the health of individuals, families and communities around the world, including the most vulnerable populations.

Today, our vibrant, entrepreneurial and committed employees bring business acumen and their collaborative spirit to help solve some of the most complex global health problems. By harnessing our collective breadth and scale, and our employees’ passion and purpose, we strive to advance health care and positively impact the lives of all people.

Our Global Public Health Strategy

We have a robust portfolio of innovative products, expertise and experience focused on maternal, newborn and child health, HIV/AIDS and tuberculosis (TB). We use holistic approaches to deliver better health outcomes in addition to quality outputs. And we bring to bear our deep expertise, talent, operational excellence, community engagement and partnerships to build a healthy world free of disease.

We work in partnership with governments, donors, non-profits and multilateral institutions to develop and deliver integrated, evidence-based solutions for public health.

Learn More About Our Efforts

What's New | HIV | Maternal and Child Health | Tuberculosis | Other GPH Initiatives | Media Center

What's New
HIV
Maternal and Child Health
Tuberculosis
Other GPH Initiatives
Media Center

What's New

Janssen Wins Prestigious International Prix Galien Award for MDR-TB Treatment

Janssen Pharmaceuticals, Inc. received the prestigious International Prix Galien, recognizing excellence in scientific innovation to improve human health.

Johnson & Johnson Global Public Health Supports World AIDS Day

With an estimated 37 million people currently living with HIV globally and 2.1 million people becoming newly infected each year, Johnson & Johnson stands united with the global community to fight HIV and care for those infected, and impacted.

The International Partnership for Microbicides’s Ring Study Results Published in The New England Journal of Medicine

Johnson & Johnson Global Public Health partner, the International Partnership for Microbicides, announced that The New England Journal of Medicine has published results from The Ring Study, a Phase III clinical trial of IPM’s vaginal ring to prevent HIV.

Paul Stoffels Speaks at the Global Citizen Festival in Montreal

Paul Stoffels, Chief Scientific Officer, Johnson & Johnson, spoke on stage at the Global Citizen Festival in Montreal about Johnson & Johnson’s efforts to end HIV.

Johnson & Johnson Achieves #2 Ranking in 2016 Access to Medicine Index

Johnson & Johnson has achieved a #2 ranking in the 2016 Access to Medicine Index for increasing access to medicines, vaccines, and diagnostics for people living in areas with high rates of poverty.

Africa Innovation Challenge Launches to Support Continent’s Entrepreneurs and Develop Local Consumer Health Solutions

Johnson & Johnson launched the Africa Innovation Challenge, an initiative that helps develop consumer health solutions that focus on three critical health areas: promoting early child development and maternal health, empowering young women, and improving family well-being.

Mebendazole Donation Supports Bangladesh National Deworming Week

Johnson & Johnson donated doses of Janssen Pharmaceutical’s mebendazole for a school-based deworming program supported by Children Without Worms and the World Health Organization, targeting approximately 29 million children to treat soil-transmitted helminthiasis in Bangladesh.

Ebola Vaccine

Partnering to Make Telangana, India Tuberculosis-free

Economic Times reported on the memorandum of understanding that Johnson & Johnson has entered into with the Telangana government in India to work together towards making the state TB-free.

Global Citizen

United Nations General Assembly Continues the Fight Against HIV, TB and Malaria

Johnson & Johnson Vice President of Innovation, Global Public Health and Science Policy Communication, Seema Kumar shares her key highlights from the Global Fund Replenishment Conference to Fight HIV, Tuberculosis and Malaria.

Billions Needed to Encourage New Drugs for Antimicrobial Resistance

Pink Sheet (subsc. req.) reported on a panel featuring Adrian Thomas, Vice President of Global Public Health at Johnson & Johnson on the importance of government financing to support antimicrobial resistance drug development during the United Nations General Assembly.

antimicrobial resistance

FDA Approves Janssen Pharmaceutical’s VERMOX™ CHEWABLE

VERMOX™ CHEWABLE treats patients one year of age and older with gastrointestinal infections caused by roundworm and whipworm infections.

antimicrobial resistance

Pharmaceutical Industry Issues Roadmap to Combat Antimicrobial Resistance

Building on the Industry Declaration made at the 2016 World Economic Forum, Johnson & Johnson joins 12 pharmaceutical companies in presenting a new roadmap that lays out four key commitments they will deliver by 2020 to reduce antimicrobial resistance.

Ebola Vaccine

Ebola Vaccine Regimen Submitted for WHO Emergency Use Assessment and Listing

If the World Health Organization grants the listing, this will accelerate the global availability of Janssen’s investigational Ebola prime-boost vaccine regimen if another Ebola crisis occurs.

Global Citizen

Partnering with Global Citizen to Improve Human Health

Johnson & Johnson partnered with social action platform Global Citizen to elevate the global importance of strong public health programs.

Ugandan Academy for Health Innovation and Impact

Ugandan Academy Launches 5 Year Strategic Plan

The Ugandan Academy for Health Innovation and Impact, funded by Janssen, launched its five-year strategic plan, including the implementation of Connect for Life™.

Tuberculosis

This New Tuberculosis Drug Could Change the World

Johnson & Johnson was named to Fortune’s 2016 Change the World list for its efforts to combat multi drug-resistant tuberculosis with the first new treatment for TB in more than 40 years.

Marburg Virus

STAT News: J&J to Start Testing Vaccine for Ebola Strains, Marburg Virus

Janssen announced the start of a first-in-human Phase 1 clinical study for its multivalent vaccine regimen to protect against Ebola, Sudan and Marburg viruses.

Janssen Antidepressant

Janssen Antidepressant Receives FDA Breakthrough Therapy Designation

Esketamine, Janssen’s investigational antidepressant medication for major depressive disorder with imminent risk of suicide, received FDA Breakthrough Therapy Designation.

HIV

6 Ways Johnson & Johnson Is Helping to Create an HIV-Free World

From education to empowerment, learn more about the ways Johnson & Johnson is making a difference for women and children.

Born on Time

Born On Time Launches in Ethiopia

World Vision launched a five-year Born On Time project in Ethiopia, the country’s first initiative to prioritize programs to prevent preterm birth.

HIV Treatment

Here’s What the Future of HIV Treatment Looks Like

Johnson & Johnson Chief Scientific Officer, Dr. Paul Stoffels, shares his perspective on the future of HIV with Business Insider.

What It Will Take to Achieve an HIV-Free World?

Johnson & Johnson leadership reflects on how the company is helping to realize the goal of ending AIDS by 2030 through innovation partnerships and R&D efforts, and the work still to be done.

Developing an HIV Vaccine

Our hope, our dream is to develop an HIV vaccine that has the potential to prevent HIV and liberate communities from HIV for good. Watch this video to learn more.

What Will It Take to Make HIV History?

The U.S. Food and Drug Administration granted Priority Review designation to Janssen’s new drug application for a chewable tablet formulation of mebendazole, which treats and prevents soil-transmitted helminthiasis, also known as intestinal worm infestations.

DREAMS Innovation Challenge Winners Announced

Janssen Pharmaceutica NV, PEPFAR and ViiV Healthcare announced a combined $85 million investment to support 56 DREAMS Innovation Challenge winners in 10 sub-Saharan African countries.

5 Ways Johnson & Johnson Is on the Fast Track to Helping End AIDS

From launching initiatives around the globe to help reduce the burden of HIV in women and children, to developing six transformational HIV medicines, we are committed to helping eliminate HIV.

Uniting for an HIV-Free World Infographic

Learn how Johnson & Johnson is building on a 25-year legacy of commitment to end HIV through innovative partnerships and investments.

AIDS 2016: Gains Against HIV Remarkable, But Not Irreversible, Experts Warn

While significant progress has been made since the 2000 International AIDS Conference in Durban, South Africa, there is still work to be done, according to this AIDS 2016 update from BioWorld.

FDA Grants Priority Review to NDA for Chewable Mebendazole Tablet

The U.S. Food and Drug Administration granted Priority Review designation to Janssen’s new drug application for a chewable tablet formulation of mebendazole, which treats and prevents soil-transmitted helminthiasis, also known as intestinal worm infestations.

FDA Grants Emergency Use Authorization to Ebola Diagnostic

The Idylla™ Ebola Virus Triage Test, jointly developed by Janssen Diagnostics, a division of Janssen Pharmaceutica, Biocartis NV (Biocartis), and the Belgium Institute of Tropical Medicine, was granted Emergency Use Authorization by the U.S. Food and Drug Administration.

Accelerating Innovation to Transform Global Health

Jaak Peeters, Head of Global Public Health, discusses financing and innovation in global health in the Spring 2016 issue of Global Health and Diplomacy.

JAMA Publishes Positive Phase 1 Data for Ebola Vaccine Regimen

The first clinical data for an Ebola prime-boost vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson have been published in JAMA: The Journal of the American Medical Association.

An Important Milestone in the Search for an Ebola Vaccine

Johnson & Johnson leadership discusses the first clinical results for a prime-boost vaccine regimen study conducted in the UK.

Johnson & Johnson Launches Global Public Health Strategy and Africa Operations

Johnson & Johnson announced the launch of its global public health strategy at the opening of its companies’ on-the-ground global public health operations in Cape Town, South Africa.

Delivering Holistic Solutions in Africa

Learn how Johnson & Johnson is taking an end-to-end approach to addressing complex global health challenges in Africa in this leadership Q&A.

Global Public Health Strategy Infographic

Read more about the principles and goals driving our global public health strategy.

Global Public Health Strategy Spotlight on Africa Infographic

Learn about Johnson & Johnson’s more than 85-year legacy of working with partners and delivering health solutions in Africa.

Helping Piece Together the HIV Puzzle

Integrated solutions focused on prevention, education and medicine are key to helping win the fight against AIDS.

R&D and Innovation in India

Janssen India leadership discusses new initiative to combat MDR-TB in India with The Hindu Business Line.

Funding Zika But Forgetting Tuberculosis

Additional support and funding is needed to help fight TB worldwide. Read more in this Health Affairs blog from Friends of the Global Fight Against AIDS, Tuberculosis and Malaria.

The Battle to End TB

Learn how Johnson & Johnson employees “Unite to End TB” and bring new hope to those suffering from tuberculosis in Vietnam, South Africa and India.

Johnson & Johnson and Janssen Support New TB Initiative in India

Times of India reports on launch of a new program to help combat MDR-TB and XDR-TB in India.

Smart Collaborations to Combat HIV

We continue to seek strategic partnerships to help make HIV history, whether it’s through collaborations between industry and non-profit organizations, public-private partnerships, or some combination of both.

First Long Acting Injectable Antiretrovirals Show Comparable Effectiveness

Phase IIb data presented at the Conference on Retroviruses and Opportunistic Infections 2016 demonstrated comparable antiviral activity between two injectable HIV medicines given together and the 3-drug oral antiretroviral therapy.

Writing a New Story for Babies to be Born on Time

While medical science has advanced leaps and bounds in recent generations, prematurity remains the top cause of newborn mortality in the United States. Learn more through this personal story.

New York Times Report on The Ring Study and ASPIRE

The New York Times reported on the results of The Ring Study and ASPIRE demonstrating that a vaginal ring containing Janssen’s antiretroviral drug helped lower HIV rates in African women.

FIND Partnership to Fight MDR-TB Featured on Devex

Devex reported on the formation of a partnership between Janssen and FIND to help step up the fight against TB, especially MDR-TB.

Calling All Innovators To Build AIDS-Free Generation

Ending AIDS would be one of the greatest accomplishments in human history. Share your innovative solution through DREAMS.

Challenging Innovators to Make DREAMS Come True

In this Huffington Post blog, USAID Ambassador Deborah L. Birx, M.D., discusses how the DREAMS partnership aims to help combat HIV in adolescent girls and young women.

6 Things Everyone Should Know About the Zika Virus

When it comes to a global public health threat, such as Zika virus, education is a powerful tool. Learn six things everyone should know.

Health Care Themes from Davos 2016

Johnson & Johnson leaders discuss how public-private partnerships will help address global health crises.

Developing A Vaccine to Combat Zika Virus

Economic Times interviews Johnson & Johnson leadership about efforts to develop a vaccine to combat Zika virus.

Helping Women Overseas Deliver Babies on Time

World Vision CEO, Debbie Wolfe, explains how the Born on Time initiative is helping to eliminate the risk factors that can lead to pre-term birth in this Huffington Post blog.

Antimicrobial Resistance: A Growing Threat

Addressing the emergence of “superbugs” and drug-resistant bacteria is critical to our economic future and global health.

Big Pharma Accelerates Fight Against “Superbugs”

Bloomberg reports on the industry-wide partnership to accelerate the development of drugs and diagnostics to help fight antimicrobial resistance.

New Collaborations to Spur Innovation in Global Public Health

Our Global Public Health strategy aims to build on our legacy by designing and delivering innovative, integrated solutions that demonstrate measurable long-term health outcomes.

 

Our Team

Johnson & Johnson’s global public health organization draws upon the breadth and scale of our cross-sector business capabilities, our global presence and expertise, and the passion, talent and entrepreneurial spirit of our employees. Our team includes senior leadership from our Consumer Health Care, Pharmaceutical and Medical Devices business segments, Corporate Affairs (Government Affairs and Policy, Communications, Corporate Equity and Corporate Citizenship) divisions, and Finance and Human Resources groups.

 

Jaak Peeters

Jaak Peeters

Jaak Peeters is the Head of Johnson & Johnson’s global public health organization. Since 1981, Jaak has served in various roles within the Janssen Pharmaceutical Companies of Johnson & Johnson, including in Europe, Middle East and Africa. Jaak is currently a Board Member of the International Federation of Pharmaceutical Manufacturers & Associations. He is based in Neuss, Germany and New Brunswick, New Jersey.

 

MEDIA CONTACTS

Seema Kumar
Seema Kumar
Vice President, Innovation, Global Public Health, and Science Policy
Telephone: +1-908-405-1144
Ernie Knewitz
Ernie Knewitz
Vice President, Global Media Relations
Telephone: +1-732-524-6623


Back to Top